CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2021—Randox Laboratories has unveiled its Qnostics Multiplex Respiratory Pathogen Controls for respiratory diseases, including for SARS-CoV-2, influenza A and B, and respiratory syncytial virus. The RTX controls are used to monitor the full testing process, from extraction to amplification and detection, and are compatible with a majority of commercial and in-house assays.
“Accurate and reliable laboratory testing is an essential aspect of the management of COVID-19 and other respiratory diseases, so we are pleased to be able to offer these new controls, which will crucially support the validation, verification, and performance monitoring of molecular respiratory assays,” Lynsey Adams, Randox quality control manager, said in a press release.